A Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab (AryoGen Pharmed) Compared With Bevacizumab (Avastin®) in Metastatic Colorectal Cancer (Q64817282)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab (AryoGen Pharmed) Compared With Bevacizumab (Avastin®) in Metastatic Colorectal Cancer |
clinical trial |
Statements
A Phase III, Randomized, Two-armed, Double-blind (Patient and Assessors), Parallel Active Controlled Non-Inferiority Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab (Produced by AryoGen Pharmed) Plus FOLFIRI-3 Compared With Bevacizumab (Avastin®) Plus FOLFIRI-3 in Patients With Metastatic Colorectal Cancer (mCRC) (English)
0 references
5 October 2016
0 references
30 July 2018
0 references
126
0 references
18 year
0 references
75 year
0 references